Coronavirus: Changes to clinical trials

INFARMED has published a set of exceptional measures – which will remain in force during the period of risk to public health – to be adopted by sponsors, clinical trial sites, and research teams, to guarantee the safety, protection and rights of clinical trial subjects.

The purpose of this information note is to make known the measures recommended by INFARMED that will be in force during the period of risk to public health.